BIOGEN INC. Effective Income Tax Rate Reconciliation Gilti Percent
BIOGEN INC. (BIIB) reported Effective Income Tax Rate Reconciliation Gilti Percent of 5.70% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-06.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent · last filed 2026-02-06
- BIOGEN INC. effective income tax rate reconciliation gilti percent for the quarter ending 2025-09-30 was -1.20%.
- BIOGEN INC. effective income tax rate reconciliation gilti percent for the quarter ending 2025-06-30 was -1.90%.
- BIOGEN INC. effective income tax rate reconciliation gilti percent for the quarter ending 2025-03-31 was 1.30%.
- BIOGEN INC. effective income tax rate reconciliation gilti percent for the quarter ending 2024-09-30 was -1.10%, a 107.43% decline year-over-year.
- BIOGEN INC. effective income tax rate reconciliation gilti percent for fiscal 2025 was 5.70%.
- BIOGEN INC. effective income tax rate reconciliation gilti percent for fiscal 2024 was -1.60%.
- BIOGEN INC. effective income tax rate reconciliation gilti percent for fiscal 2023 was -0.60%, a 185.71% decline from fiscal 2022.
- BIOGEN INC. effective income tax rate reconciliation gilti percent for fiscal 2022 was 0.70%, a 46.15% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation Gilti Percent 3 month | Effective Income Tax Rate Reconciliation Gilti Percent 3 month as first filed | Effective Income Tax Rate Reconciliation Gilti Percent 6 month | Effective Income Tax Rate Reconciliation Gilti Percent 9 month | Effective Income Tax Rate Reconciliation Gilti Percent 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | 5.70% 10-K · filed 2026-02-06 | ||||
| 2025-09-30 | -1.20% 10-Q · filed 2025-10-30 | -1.00% 10-Q · filed 2025-10-30 | |||
| 2025-06-30 | -1.90% 10-Q · filed 2025-07-31 | -1.00% 10-Q · filed 2025-07-31 | |||
| 2025-03-31 | 1.30% 10-Q · filed 2025-05-01 | ||||
| 2024-12-31 | -1.60% 10-K · filed 2026-02-06 | ||||
| 2024-09-30 | -1.10% 10-Q · filed 2025-10-30 | -1.40% 10-Q · filed 2025-10-30 | |||
| 2024-06-30 | -0.90% 10-Q · filed 2025-07-31 | -1.60% 10-Q · filed 2025-07-31 | |||
| 2024-03-31 | -2.70% 10-Q · filed 2025-05-01 | -2.60% 10-Q · filed 2024-04-24 | |||
| 2023-12-31 | -0.60% 10-K · filed 2026-02-06 | ||||
| 2023-09-30 | 14.80% 10-Q · filed 2024-10-30 | -1.70% 10-Q · filed 2024-10-30 | |||
| 2023-06-30 | 0.20% 10-Q · filed 2024-08-01 | 0.30% 10-Q · filed 2024-08-01 | |||
| 2023-03-31 | 0.50% 10-Q · filed 2024-04-24 | ||||
| 2022-12-31 | 0.70% 10-K · filed 2025-02-12 | ||||
| 2022-09-30 | 0.80% 10-Q · filed 2023-11-08 | 0.50% 10-Q · filed 2023-11-08 | |||
| 2021-12-31 | 1.30% 10-K · filed 2024-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |